Joanna L Starrels1, Sarah R Young2,3, Soraya S Azari4, William C Becker5,6, E Jennifer Edelman5, Jane M Liebschutz7, Jamie Pomeranz8, Payel Roy9, Shalini Saini10, Jessica S Merlin7. 1. Division of General Internal Medicine, Albert Einstein College of Medicine and Montefiore Health System, Bronx, New York. 2. Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Social Work, College of Community and Public Affairs, Binghamton University, Binghamton, New York. 4. Division of General Internal Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California. 5. Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. 6. VA Connecticut Healthcare System, West Haven, Connecticut. 7. Division of General Internal Medicine, Center for Research on Health Care, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 8. Department of Occupational Therapy, University of Florida, Gainesville, Florida. 9. Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts. 10. Department of Medicine, Information Technology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
BACKGROUND: Marijuana use is common among patients on long-term opioid therapy (LTOT) for chronic pain, but there is a lack of evidence to guide clinicians' response. OBJECTIVE: To generate expert consensus about responding to marijuana use among patients on LTOT. DESIGN: Analysis from an online Delphi study. SETTING/ SUBJECTS: Clinician experts in pain and opioid management across the United States. METHODS: Participants generated management strategies in response to marijuana use without distinction between medical and nonmedical use, then rated the importance of each management strategy from 1 (not at all important) to 9 (extremely important). A priori rules for consensus were established, and disagreement was explored using cases. Thematic analysis of free-text responses examined factors that influenced participants' decision-making. RESULTS: Of 42 participants, 64% were internal medicine physicians. There was consensus that it is not important to taper opioids as an initial response to marijuana use. There was disagreement about the importance of tapering opioids if there is a pattern of repeated marijuana use without clinical suspicion for a cannabis use disorder (CUD) and consensus that tapering is of uncertain importance if there is suspicion for CUD. Three themes influenced experts' perceptions of the importance of tapering: 1) benefits and harms of marijuana for the individual patient, 2) a spectrum of belief about the overall riskiness of marijuana use, and 3) variable state laws or practice policies. CONCLUSIONS: Experts disagree and are uncertain about the importance of opioid tapering for patients with marijuana use. Experts were influenced by patient factors, provider beliefs, and marijuana policy, highlighting the need for further research.
BACKGROUND:Marijuana use is common among patients on long-term opioid therapy (LTOT) for chronic pain, but there is a lack of evidence to guide clinicians' response. OBJECTIVE: To generate expert consensus about responding to marijuana use among patients on LTOT. DESIGN: Analysis from an online Delphi study. SETTING/ SUBJECTS: Clinician experts in pain and opioid management across the United States. METHODS:Participants generated management strategies in response to marijuana use without distinction between medical and nonmedical use, then rated the importance of each management strategy from 1 (not at all important) to 9 (extremely important). A priori rules for consensus were established, and disagreement was explored using cases. Thematic analysis of free-text responses examined factors that influenced participants' decision-making. RESULTS: Of 42 participants, 64% were internal medicine physicians. There was consensus that it is not important to taper opioids as an initial response to marijuana use. There was disagreement about the importance of tapering opioids if there is a pattern of repeated marijuana use without clinical suspicion for a cannabis use disorder (CUD) and consensus that tapering is of uncertain importance if there is suspicion for CUD. Three themes influenced experts' perceptions of the importance of tapering: 1) benefits and harms of marijuana for the individual patient, 2) a spectrum of belief about the overall riskiness of marijuana use, and 3) variable state laws or practice policies. CONCLUSIONS: Experts disagree and are uncertain about the importance of opioid tapering for patients with marijuana use. Experts were influenced by patient factors, provider beliefs, and marijuana policy, highlighting the need for further research.
Authors: Joao P De Aquino; Mohamed Sherif; Rajiv Radhakrishnan; John D Cahill; Mohini Ranganathan; Deepak C D'Souza Journal: Clin Ther Date: 2018-04-17 Impact factor: 3.393
Authors: Phoebe A Cushman; Jane M Liebschutz; Joseph G Hodgkin; Christopher W Shanahan; Julie L White; Ilana Hardesty; Daniel P Alford Journal: Subst Abus Date: 2017-04-10 Impact factor: 3.716
Authors: Judith A Turner; Kathleen Saunders; Susan M Shortreed; Linda LeResche; Kim Riddell; Suzanne E Rapp; Michael Von Korff Journal: J Gen Intern Med Date: 2014-09-13 Impact factor: 5.128
Authors: Shannon M Nugent; Bobbi Jo Yarborough; Ning X Smith; Steven K Dobscha; Richard A Deyo; Carla A Green; Benjamin J Morasco Journal: Gen Hosp Psychiatry Date: 2017-11-08 Impact factor: 3.238
Authors: Jessica S Merlin; Sarah R Young; Soraya Azari; William C Becker; Jane M Liebschutz; Jamie Pomeranz; Payel Roy; Shalini Saini; Joanna L Starrels; E Jennifer Edelman Journal: BMJ Open Date: 2016-05-06 Impact factor: 2.692